<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253796</url>
  </required_header>
  <id_info>
    <org_study_id>8259-038</org_study_id>
    <secondary_id>2015-004020-65</secondary_id>
    <nct_id>NCT03253796</nct_id>
  </id_info>
  <brief_title>Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (MK-8259-038)</brief_title>
  <official_title>A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of treatment withdrawal vs continued
      treatment with golimumab (GLM) administered by subcutaneous (SC) injection on the incidence
      of a &quot;flare&quot; in non-radiographic axial spondyloarthritis over up to 12 months. The primary
      hypothesis is that continued treatment with golimumab is superior to treatment withdrawal,
      based on the percentage of subjects without a &quot;flare&quot; during up to 12 months of blinded
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>To evaluate the effect of treatment withdrawal vs continued treatment with golimumab (either every month [QM] or every 2 months [Q2M]) on the incidence of a &quot;flare&quot; during up to 12 months in Period 2 (blinded therapy).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Flare</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants without a disease activity &quot;flare&quot; during up to 12 months following randomization to DB therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants with a clinical response to re-treatment with OL golimumab after a &quot;flare&quot; in Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Flare</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time to first &quot;flare&quot; in Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment in SpondyloArthritis international Society (ASAS)20 Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants achieving ASAS20 response (20% reduction in ASAS) in Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS40 Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants achieving ASAS40 response (40% reduction in ASAS) in Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)50 Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants achieving a BASDAI50 response (250% reduction in BSDAI) in Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS Partial Remission</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants achieving ASAS partial remission in Period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inactive Disease Status</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Percentage of participants achieving inactive disease status in Period 2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 12 months, plus AE follow up</time_frame>
    <description>Number of participants who experience at lease one adverse event (AE)</description>
  </other_outcome>
  <other_outcome>
    <measure>Discontinuations</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Number of participants who discontinue treatment due to an AE</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Open-label (OL) GLM SC QM ---&gt; PBO SC QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with placebo (PBO) SC QM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OL GLM SC QM ---&gt; DB GLM SC QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with double-blinded (DB) GLM SC QM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OL GLM SC QM ---&gt; DB GLM SC Q2M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with DB GLM SC Q2M</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Golimumab QM: Period 1 (OL)</intervention_name>
    <description>OL monthly injections of active golimumab 50 mg or 100 mg (two 50 mg injections) from Month 0 to Month 9 (Period 1, run-in)</description>
    <arm_group_label>OL GLM SC QM ---&gt; DB GLM SC Q2M</arm_group_label>
    <arm_group_label>OL GLM SC QM ---&gt; DB GLM SC QM</arm_group_label>
    <arm_group_label>Open-label (OL) GLM SC QM ---&gt; PBO SC QM</arm_group_label>
    <other_name>MK-8259</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Golimumab QM: Period 2 (DB)</intervention_name>
    <description>DB monthly injections of active golimumab 50 mg or 100 mg (two 50 mg injections) for 12 months, or until &quot;flare&quot; (Period 2, full treatment)</description>
    <arm_group_label>OL GLM SC QM ---&gt; DB GLM SC QM</arm_group_label>
    <other_name>MK-8259</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Golimumab Q2M: Period 2 (DB)</intervention_name>
    <description>DB monthly injections of golimumab 50 mg or 100 mg (two 50 mg injections), alternating with placebo, for 12 months, or until &quot;flare&quot; (Period 2, reduced treatment)</description>
    <arm_group_label>OL GLM SC QM ---&gt; DB GLM SC Q2M</arm_group_label>
    <other_name>MK-8259</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo QM: Period 2 (DB)</intervention_name>
    <description>DB monthly injections of placebo for golimumab for 12 months, or until &quot;flare&quot; (Period 2, treatment withdrawal)</description>
    <arm_group_label>Open-label (OL) GLM SC QM ---&gt; PBO SC QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Golimumab QM: Period 2 (OL)</intervention_name>
    <description>OL golimumab 50 mg or 100 mg (two 50 mg injections) for 12 months (Period 2, full treatment re-started after &quot;flare&quot;)</description>
    <arm_group_label>Open-label (OL) GLM SC QM ---&gt; PBO SC QM</arm_group_label>
    <other_name>MK-8259</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is not of reproductive potential, or is of reproductive potential and agrees to avoid
             becoming pregnant or impregnating a partner while receiving trial medication or within
             6 months after the last dose of trial medication

          -  Has chronic back pain of ≥3 months duration by history

          -  Has physician-diagnosed active nr-axSpA with disease duration &lt;= 5 years

          -  Has active inflammation on magnetic resonance imaging (MRI) highly suggestive of
             sacroiliitis associated with spondyloarthropathy and 1 or more of the following
             spondyloarthritis (SpA) characteristics:

               -  • Inflammatory back pain

               -  • Arthritis (physician-diagnosed)

               -  • Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at
                  examination of the site of the insertion of the Achilles tendon or plantar
                  fascia)

               -  • Dactylitis (physician-diagnosed)

               -  • Psoriasis (physician-diagnosed)

               -  • History of physician-diagnosed inflammatory bowel disease (IBD)

               -  • History of uveitis confirmed by an ophthalmologist

               -  • Good response to nonsteroidal anti-inflammatory drugs (NSAID)

               -  • Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute
                  uveitis, reactive arthritis, or IBD)

               -  • Elevated CRP

               -  • Human leukocyte antigen B27 (HLA-B27)+ gene

          -  Has a HLA-B27+ gene and 2 or more of the SpA characteristics listed above

          -  Has elevated CRP at Screening or evidence of active inflammation in the sacroiliac
             joints on MRI

          -  Has an ASDAS &gt;= 2.1 at Screening

          -  Shows high disease activity at Screening and Baseline of both a Total Back Pain score
             of ≥4 and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of &gt;= 4

          -  Has an acceptable history of NSAID use

          -  Has no history of untreated latent or active tuberculosis (TB) prior to Screening

          -  Has had no recent close contact with a person with active TB or, if there has been
             such contact, will undergo additional evaluations and receive appropriate treatment
             for latent TB

        Exclusion Criteria:

          -  Has bilateral sacroiliitis Grade 2 or unilateral sacroiliitis Grade 3 or Grade 4

          -  Is a nursing or pregnant female, or intends to become pregnant within 6 months after
             receiving trial medication

          -  Intends to donate eggs (female participants) or sperm (male participants) while
             receiving trial medication or within 6 months after trial medication

          -  Has any clinically significant condition or situation that would interfere with the
             trial evaluations or participation in the trial

          -  Has ever received any cytotoxic drugs, including chlorambucil, cyclophosphamide,
             nitrogen mustard, or other alkylating agents

          -  Has received any treatment listed below more recently than the indicated off-drug
             period prior to Screening

               -  • Disease-modifying anti-rheumatic drugs (30 days off drug)

               -  • Live vaccinations (3 months off drug)

               -  • Investigational medications (30 days or 5 half-lives off drug, whichever is
                  longer)

               -  • Bacille Calmette-Guerin (BCG) vaccination (12 months off drug)

          -  Has any systemic inflammatory condition, including psoriatic arthritis, active Lyme
             disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus
             infection, rheumatoid arthritis, active uveitis, or active IBD

          -  Has a history of latent or active granulomatous infection prior to Screening

          -  Had a nontuberculous mycobacterial infection or opportunistic infection within 6
             months prior to Screening

          -  Has a history of an infected joint prosthesis, or has received antibiotics for a
             suspected infection of a joint prosthesis, if that prosthesis has not been removed or
             replaced

          -  Had a serious infection, has been hospitalized for an infection, or has been treated
             with IV antibiotics for an infection within 2 months prior to Baseline

          -  Had a history of, or ongoing, chronic or recurrent infectious disease

          -  Is known to be infected with human immunodeficiency virus (HIV) or seropositive for
             hepatitis C virus (HCV)

          -  Has had a chest x-ray within 2 months prior to Screening that shows an abnormality
             suggestive of a current active infection or malignancy

          -  Has a history of lymphoproliferative disease

          -  Has had a malignancy within 5 years before screening (exceptions are squamous and
             basal cell carcinomas of the skin and carcinoma in situ of cervix that has been
             surgically cured)

          -  Has a history of known demyelinating diseases such as multiple sclerosis or optic
             neuritis

          -  Has a history of or concurrent congestive heart failure of any grade

          -  Has a transplanted organ (with the exception of a corneal transplant performed &gt;= 3
             months prior to baseline)

          -  Has current signs or symptoms of significant medical illness which could interfere
             with the trial, or require treatment that might interfere with the trial

          -  Is a user of recreational or illicit drugs or has or had a substance abuse (drug or
             alcohol) problem within the previous 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FN Brno ( Site 0005)</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie s.r.o. ( Site 0009)</name>
      <address>
        <city>Brno</city>
        <zip>638 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artroscan s.r.o. ( Site 0007)</name>
      <address>
        <city>Ostrava-Trebovice</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Ostrava s.r.o. ( Site 0001)</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Czech a.s. ( Site 0003)</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Prague s.r.o ( Site 0004)</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole ( Site 0127)</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Plus s.r.o ( Site 0010)</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV - Medical s.r.o. ( Site 0006)</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik der Charite Berlin ( Site 0023)</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet ( Site 0021)</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U. klinikum Koeln AOER ( Site 0025)</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - LMU ( Site 0026)</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Kellner Innere Medizin Rheumatologie und Gastroenterologie ( Site 0022)</name>
      <address>
        <city>Muenchen</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis Sneek ( Site 0043)</name>
      <address>
        <city>Sneek</city>
        <state>Friesland</state>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrij Universiteit Medisch Centrum ( Site 0044)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum ( Site 0041)</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis ( Site 0042)</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Katowice ( Site 0059)</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska, Dr. med. Pawel Hrycaj ( Site 0060)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Osteo-Medic s.c. A. Racewicz, R. Supronik ( Site 0058)</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej ( Site 0153)</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kliniczno-Badawcze ( Site 0152)</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakow Medical Centre ( Site 0052)</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Reumed ( Site 0051)</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pomorskie Cent. Reumatologiczne IM.Dr. Titz-Kosko W Sopocie Sp. Z.o.o. ( Site 0057)</name>
      <address>
        <city>Sopot</city>
        <zip>81-759</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne ( Site 0053)</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz Praktyka Grupowa Lekarzy Rodzinnych ( Site 0151)</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatika ( Site 0055)</name>
      <address>
        <city>Warszawa</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical de Diagnostic si Tratament Ambulator Neomed ( Site 0177)</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Ioan Cantacuzino ( Site 0184)</name>
      <address>
        <city>Bucaresti</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colentina Clinical Hospital ( Site 0231)</name>
      <address>
        <city>Bucarest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Sfanta Maria ( Site 0182)</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Duo Medical SRL ( Site 0183)</name>
      <address>
        <city>Bucuresti</city>
        <zip>010584</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj-Napoca ( Site 0176)</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RKMed Center ( Site 0180)</name>
      <address>
        <city>Iasi</city>
        <zip>700127</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C.Pelican Impex S.R.L ( Site 0232)</name>
      <address>
        <city>Oradea</city>
        <zip>410450</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covamed Serv SRL ( Site 0178)</name>
      <address>
        <city>Sfantu Gheorghe</city>
        <zip>520052</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical Medicina Interna Dr. Triff Carina ( Site 0179)</name>
      <address>
        <city>Timisoara</city>
        <zip>300766</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ Regional Clinical Hospital ( Site 0076)</name>
      <address>
        <city>Saratov</city>
        <state>Oktyabrskiy Region</state>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Institute n.a. V.A.Nasonova of RAMS ( Site 0061)</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBHI Clinical Rheumatological Hospital 25 ( Site 0077)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI Leningrad Regional Clinical Hospital ( Site 0065)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Sanavita ( Site 0074)</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tolyatti City Clinical Hospital 5 ( Site 0069)</name>
      <address>
        <city>Tolyatti</city>
        <zip>445039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Clinical Hospital for Emergency Care na. NV. Solovyev. ( Site 0075)</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto ( Site 0082)</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia ( Site 0081)</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0083)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Arrixaca ( Site 0085)</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz Universitesi Tip Fakultesi Romatoloji Departmani ( Site 0094)</name>
      <address>
        <city>Antalya</city>
        <state>Ankara</state>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Numune Egitim Arastirma Hastanesi ( Site 0092)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0091)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tıp Fakultesi ( Site 0093)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamukkale Unv. Tip Fak. ( Site 0097)</name>
      <address>
        <city>Denizli</city>
        <zip>20070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0098)</name>
      <address>
        <city>Istanbul</city>
        <zip>34899</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli Universitesi Tip Fakultesi Ic Hastaliklari ( Site 0096)</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkassy Regional hospital of Cherkassy Regional council ( Site 0221)</name>
      <address>
        <city>Cherkassy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 0222)</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI National Institute of therapy n.a L.T. Maloi NAMS of Ukraine ( Site 0261)</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ME of Health Care Kharkiv City Clinical Hospital #8 ( Site 0262)</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyivska miska klinichna likarnia N3 ( Site 0266)</name>
      <address>
        <city>Kyiv</city>
        <zip>02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Strazhesko Institute of Cardiology. ( Site 0264)</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ibn Sina ( Site 0268)</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Modern Rheumatology ( Site 0265)</name>
      <address>
        <city>Kyiv</city>
        <zip>04070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal City Clinical Hospital #4 ( Site 0230)</name>
      <address>
        <city>Lviv</city>
        <zip>79011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MI Odesa Regional Clinical Hospital ( Site 0226)</name>
      <address>
        <city>Odesa</city>
        <zip>65117</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V.Sklifosovskyi Poltava Regional Clinical Hospital ( Site 0224)</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnitsa Regional Clinical Hospital n.a. Pirogov ( Site 0225)</name>
      <address>
        <city>Vinnutsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRI of Invalid Rehabilitation of Vinnytsia M.I.Pyrogov ( Site 0263)</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhzha Regional Clinical Hospital ( Site 0223)</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Estonia</country>
    <country>Ireland</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

